Metabolic and hormonal effects of preferential beta 1 and beta 2-adrenoceptor stimulation in man

Journal of Endocrinological Investigation
C TantucciV Grassi


The changes of blood glucose, serum potassium (K+), plasma non-esterified fatty acids (NEFA), plasma insulin and plasma renin activity (PRA) following the preferential stimulation of beta-1 and beta-2 adrenoceptors were studied in 7 healthy subjects during a 60-min infusion of prenalterol, a new, relatively beta-1 selective agonist and salbutamol, a well known, relatively beta-2 selective agonist. Two different high and low doses were used for both agents: 300 micrograms and 600 micrograms and 1 mg and 2 mg for salbutamol and prenalterol, respectively. The levels of PRA seemed equally increased by the two agents in proportion to the dose infused, thus suggesting an equally important role for beta-1 and beta-2 adrenoceptors in renin release. Blood glucose did not change during prenalterol infusions, while increased by 12 +/- 2 mg/100 ml (mean +/- SE; p less than 0.01) and 25 +/- 3 mg/100 ml (p less than 0.01) on salbutamol, at low and high dose, respectively. Similarly the decrement of serum K+ was significantly more pronounced (p less than 0.01) after salbutamol infusion (0.6 +/- 0.07 mEq/L and 1.0 less than 0.09 mEq/L, at low and high dose, respectively) than after prenalterol (0.1 +/- 0.07 mEq/L and 0.3 +/- 0.05 mEq/L). These...Continue Reading


Mar 1, 1976·Acta Physiologica Scandinavica·L Stjärne, J Brundin
Nov 10, 1977·Naunyn-Schmiedeberg's Archives of Pharmacology·E CarlssonB Tångstrand
Apr 1, 1979·British Journal of Clinical Pharmacology·D H ScottD B Scott
Aug 13, 1977·British Medical Journal·D J ThomasW A Stubbs
Sep 17, 1977·British Medical Journal·D Leslie, P M Coats
Sep 1, 1979·Clinical Pharmacology and Therapeutics·N WinerR M Bell
Feb 1, 1979·British Journal of Clinical Pharmacology·P LijnenA F De Schaepdryver
Jan 3, 1976·British Medical Journal·M W TaylorK N Palmer
Mar 5, 1977·British Medical Journal·M G Chapman
Feb 1, 1975·Postgraduate Medical Journal·R GoldbergH C Seftel
May 1, 1974·The Journal of Clinical Investigation·J E GerichP H Forsham
Oct 1, 1965·The Journal of Clinical Endocrinology and Metabolism·V HerbertS J Bleicher
Jan 1, 1967·The Journal of Clinical Investigation·D Porte
Apr 15, 1980·Klinische Wochenschrift·K A MeurerA Helber
Feb 1, 1981·European Journal of Biochemistry·B JacobssonA D Strosberg
Jan 1, 1981·Annual Review of Neuroscience·K P MinnemanP B Molinoff
Nov 1, 1983·British Journal of Clinical Pharmacology·J StaessenA Amery
Apr 1, 1984·Physiological Reviews·G L StilesR J Lefkowitz
Mar 1, 1980·The Journal of Clinical Investigation·R A RizzaJ E Gerich
Aug 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·T NakakiR Kato
Apr 1, 1983·Clinical Pharmacology and Therapeutics·J E BrownD G Shand
Jul 1, 1960·The Journal of Clinical Investigation·R S YALOW, S A BERSON


Dec 3, 1999·British Journal of Clinical Pharmacology·S M FreudenthalerC H Gleiter
Oct 16, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Wendy W WatersJanice V Meck

Related Concepts

Blood Glucose
Nonesterified Fatty Acids
Insulin B Chain
Prenalterol Hydrochloride
Beta-adrenergic receptor

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.